Trial Profile
Study of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin for treatment of HCV-GT4 in Egyptian patients with severe renal impairment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2018
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 16 May 2018 New trial record
- 14 Apr 2018 Results presented at The International Liver Congress 2018